Cornerstone Advisors (Washington)’s Takeda Pharmaceutical TAK Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$83K	Buy	4,641 +234	+5%	+$4.26K	0.01%	193
2020 Q2	$79K	Buy	4,407 +1,264	+40%	+$22.7K	0.01%	195
2020 Q1	$48K	Sell	3,143 -364	-10%	-$6.6K	0.01%	224
2019 Q4	$69K	Buy	3,507 +634	+22%	+$12.1K	0.01%	198
2019 Q3	$49K	Buy	2,873 +1,252	+77%	+$21.7K	0.01%	223
2019 Q2	$29K	Sell	1,621 -649	-29%	-$11.8K	﹤0.01%	563
2019 Q1	$46K	Buy	2,270 +1,944	+596%	+$39.1K	﹤0.01%	392
2018 Q4	$5K	Buy	+326	New	+$5.5K	﹤0.01%	776

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cornerstone Advisors (Washington)'s TAK Position: Q3 2020 in Review

Cornerstone Advisors (Washington) increased its Takeda Pharmaceutical (TAK) stake by 5.3% in Q3 2020, buying an estimated $4.26K and bringing the position to 4,641 shares worth $83K. The position accounts for 0.01% of the portfolio, ranked #193.

Cornerstone Advisors (Washington) first reported a position in TAK in Q4 2018 and has held it in 8 quarters since. 311 funds tracked by Wall St. Rank hold TAK as of Q3 2020.

Cornerstone Advisors (Washington) held 4,641 shares of Takeda Pharmaceutical worth $83K as of Q3 2020.
Cornerstone Advisors (Washington) bought 234 Takeda Pharmaceutical shares in Q3 2020, an estimated $4.26K.
Takeda Pharmaceutical made up 0.01% of Cornerstone Advisors (Washington)'s portfolio in Q3 2020, its #193 holding.
Cornerstone Advisors (Washington) first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 8 quarters since.
311 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2020.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2020, filed 20 Oct 2020.